Tiziana life sciences plc ("tiziana" or the "company") - tiziana announces completion of the clinical trial with nasally administered foralumab, its proprietary fully human anti-cd3 monoclonal antibody, for the treatment of covid-19 patients in brazil

New york and london, jan. 04, 2021 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa / aim: tils) (“tiziana” or the “company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the completion of its clinical study in brazil investigating nasally administered foralumab, its proprietary human monoclonal antibody, either alone or in combination with orally administered dexamethasone in covid-19 patients.
TLSA Ratings Summary
TLSA Quant Ranking